



Company Announcement

Nykode Therapeutics Announces Expansion of Oncology Pipeline Aiming to Reduce the Burden of Colorectal Cancer

- Expansion of oncology pipeline with preclinical program aiming to reduce the burden of colorectal cancer.
- First-in-class approach building on Nykode's 2nd generation technology and novel antigen combination.
- Aim to address distinct patient populations ranging from high-risk pre-cancerous polyps to colorectal cancer.
- Executing on the company's strategy to develop a portfolio to reduce cancer at all stages of cancer development.

Oslo, Norway, December 14, 2023 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced an expansion of the pipeline with a potential first-in-class preclinical oncology vaccine program aimed at preventing and treating colorectal cancer.

Colorectal cancer begins as a premalignant polyp that grows on the mucosal surface of the colon or rectum and transforms into malignancy. The disease development and screening programs represent an opportunity to identify and treat high-risk patients at early stages in addition to treating patients with developed malignancies.

Nykode's novel vaccines are based on a careful selection and combination of highly expressed tumor associated antigens involved in the development and progression of colonic polyps to colorectal cancer. The program will incorporate Nykode's 4th module proprietary second-generation technology to further optimize the immune responses tailored to diverse target populations. The program builds on Nykode's differentiating competence of creating broad and robust CD8 T cell responses with the potential to break tolerance against tumor-associated antigens, as illustrated by data presented at Nykode's recent Capital Market Day. Strong preclinical data generated in the discovery phase further supports the induction of potent CD8 T cell responses in both wild-type and HLA transgenic mice models.

"I am thrilled about this exciting addition to our pipeline, which underscores Nykode's dedication to creating innovative solutions for an expanding range of patients in need of alternative therapies," said Mikkel W. Pedersen, Nykode's Chief Scientific Officer. "Additionally, it signifies our belief in the promise of cancer vaccines across all stages of cancer development."

"The potential first-in-class program reaffirms Nykode's vision of building a balanced cancer vaccine portfolio. We are excited about the transformative power of our next-generation technology with the potential to reduce the burden of colorectal cancer," commented Michael Engsig, CEO of Nykode.



About Nykode Therapeutics

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode's modular vaccine technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer. VB10.16 is being expanded into multiple trials for treatment of head and neck cancer and cervical cancer. VB10.NEO, an individualized cancer neoantigen vaccine, is exclusively out-licensed to Genentech, a member of the Roche Group.

The Company's partnerships include Genentech within oncology and a multi-target collaboration with Regeneron in oncology and infectious diseases.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at <http://www.nykode.com>.

Forward-looking statements for Nykode Therapeutics

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:

Alexandra Deschner, Head of IR
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA

Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway